Reducing drug costs at a Veterans Affairs hospital by increasing market-share of generic fluoxetine.
We previously showed that a multifaceted intervention designed to contain costs of prescribing selective serotonin reuptake inhibitors (SSRIs) at a Veterans Affairs hospital resulted in substantial projected savings. Intervention components included clinician education and pharmacy and computer information process changes. We now report on effects of altering the intervention to promote prescribing of generic fluoxetine. Over 30 months, fluoxetine's market-share increased from 12 to 32% of all SSRIs prescribed. A total of $2,500,000 in cost avoidance resulted from substituting generic for brand fluoxetine, and $600,000 resulted from increases in market-share of fluoxetine. The results highlight the robustness and flexibility of the intervention approach.
Dobscha
Steven K
SK
Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Portland, OR 97207, USA. steven.dobscha@med.va.gov
Winterbottom
Lisa M
LM
Snodgrass
Leann S
LS
D003363:Cost Control; D016527:Drug Costs; D016568:Drugs, Generic; D004465:Economic Competition; D005473:Fluoxetine / Q000191:economics*; D006787:Hospitals, Veterans / Q000191:economics*; D009922:Oregon; D019982:Organizational Case Studies
D016568:Drugs, Generic; D005473:Fluoxetine